Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)

Inclusion criteria

• Male aged 45 years old and above (with no upper limit of age)
• patients who underwent combination therapy of alpha blocker and 5 ARI for more than 9 months
• IPSS ≤ 12
• Ability and willingness to correctly complete the micturition diary and questionnaire
• Capable of understanding and having signed the informed consent form after full discussion of the research nature of the treatment and its risks and benefits

Exclusion criteria

• An anticholinergic or antidiuretic if started less than 3 months prior to screening
• Patients who had surgical treatment due to LUTS
• Patients with suspected neurogenic bladder disorder
• Patients with cancer of any type including cancer of the prostate or bladder
• Patients with urethral stricture or bladder neck contracture
• Patients with suspicious chronic prostatitis/chronic pelvic pain syndrome
• Acute bacterial prostatitis less than 6 months prior to screening
• Symptomatic acute urinary tract infection (UTI) less than 1 months prior to screening
• Patients who had underwent prostatic biopsy less than one month prior to screening
• Patients who had unstable angina or cerebral vascular disease less than 6 months prior to screening